Advertisement

Mortality and natural progression of type 1 diabetes patients enrolled in the Rwanda LFAC program from 2004 to 2012

  • Sara L. Marshall
  • Deborah V. Edidin
  • Vincent C. Arena
  • Dorothy J. Becker
  • Clareann H. Bunker
  • Crispin Gishoma
  • Francois Gishoma
  • Ronald E. LaPorte
  • Vedaste Kaberuka
  • Graham Ogle
  • Wilson Rubanzana
  • Laurien Sibomana
  • Trevor J. Orchard
Original Article

Abstract

The natural history and mortality of type 1 diabetes in adolescents in Africa is not well characterized. Our aim is, therefore, to describe these characteristics for cases in the Rwanda Life For a Child (LFAC) program. Participants (≤25 years old) were the first 500 children and youth enrolled in the Rwanda LFAC program from 2004 to 2012. Clinical and demographic data were extracted from LFAC forms, and vital status was evaluated as of November 1, 2011. For the first 500 participants, 5-year survival was 93.8% while crude mortality was 13.9/1000 (95% CI 9.0–20.6/1000) person years of diabetes. However, since vital status is unknown for 134 participants, mortality could be as high as 40.2/1000 person years of diabetes if all missing cases died. Mortality was directly associated with age at diagnosis, and inversely to calendar year of first visit, BMI, and monitoring frequency. Hypertension prevalence reached 46% by 2012. Mortality rates associated with type 1 diabetes in Rwanda are similar to those in other African countries, but higher than rates in developed countries. Delayed diagnosis may contribute to excess mortality risk, but recent improvements in survival suggest that advancements are being made. Hypertension and loss to follow-up need to be addressed.

Keywords

Type 1 diabetes Youth Children Natural history Rwanda Africa 

Notes

Acknowledgements

We would like to thank the staff of the ARD in Kigali for all of the help and support they have given to us throughout this project. We also thank the Ministry of Health and Rwanda Biomedical Center for their assistance and guidance. We would also like to acknowledge the LFAC program for providing us with the opportunity to work with them and the ARD. Finally, we thank the wonderful children and youth with diabetes and their caregivers for their willing acceptance of help and the dignity and courage they show in coping with diabetes in the most difficult circumstances.

Compliance with ethical standards

Funding

No funding was received for this study. Insulin, syringes, glucose meters, and strips were received free from the LFAC program. DCA machines, HbA1C, and A/C reagents were provided by the University of Pittsburgh.

Conflict of interest

Sara L. Marshall, Deborah V. Edidin, Vincent C. Arena, Dorothy J. Becker, Clareann H. Bunker, Crispin Gishoma, Francois Gishoma, Ronald E. LaPorte, Vedaste Kaberuka, Graham Ogle, Wilson Rubanzana, and Laurien Sibomana have no conflict-of- interest to declare. Dr. Trevor Orchard serves on Eli Lilly and Company Advisory Panel.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Authors’ contributions

Marshall SL designed the study, performed research and analysis and wrote the paper; Orchard TJ designed the study, reviewed analysis, revised the manuscript; Edidin DV, Gishoma C, Gishoma F, Kaberuka V, Sibomana L, and Rubanzana W performed research, collected data, and revised the manuscript; Arena VC reviewed analysis and revised the manuscript; Becker DJ, Bunker CH, Ogle G, and LaPorte RE provided oversight and revised the manuscript.

References

  1. 1.
    International Diabetes Federation. Diabetes atlas, fourth edition. Brussels, Belgium; 2009.Google Scholar
  2. 2.
    Marshall SL, Edidin D, Sharma V, Ogle G, Arena VC, Orchard T. Current clinical status, glucose control, and complication rates of children and youth with type 1 diabetes in Rwanda. Pediatr Diabetes. 2013;14(3):217–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Walsh MG, Zgibor J, Borch-Johnsen K, Orchard TJ. A multinational assessment of complications in type 1 diabetes: the DiaMond substudy of complications (DiaComp) level 1. Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease. 2006;3(2):80–3.CrossRefGoogle Scholar
  4. 4.
    Lester FT. Clinical features, complications and mortality in type 1 (insulin-dependent) diabetic patients in Addis Ababa, Ethiopia, 1976–1990. The Quarterly journal of medicine. 1992;83(301):389–99.PubMedGoogle Scholar
  5. 5.
    Gill GV, Huddle KRL, Monkoe G. Long-term (20 years) outcome and mortality of Type 1 diabetic patients in Soweto, South Africa. Diabetic Medicine. 2005;22(12):1642–6.CrossRefPubMedGoogle Scholar
  6. 6.
    McLarty DG, Athaide I, Bottazzo GF, Swai AM, Alberti KG. Islet cell antibodies are not specifically associated with insulin-dependent diabetes in Tanzanian Africans. Diabetes Res Clin Pract. 1990;9(3):219–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990–96. Arch Dis Child. 1999;81(4):318–23.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Podar T, Solntsev A, Reunanen A, Urbonaite B, Zalinkevicius R, Karvonen M, LaPorte RE, Tuomilehto J. Mortality in patients with childhood-onset type 1 diabetes in Finland, Estonia, and Lithuania: follow-up of nationwide cohorts. Diabetes Care. 2000;23(3):290–4.CrossRefPubMedGoogle Scholar
  9. 9.
    O’Grady MJ, Delaney J, Jones TW, Davis EA. Standardised mortality is increased three-fold in a population-based sample of children and adolescents with type 1 diabetes. Pediatr Diabetes. 2013;14(1):13–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Warner DP, McKinney PA, Law GR, Bodansky HJ. Mortality and diabetes from a population based register in Yorkshire 1978-93. Arch Dis Child. 1998;78(5):435–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59(12):3216–22.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care. 2010;33(12):2573–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Beran D, Yudkin JS, De Courten M. Access to care for patients with insulin-requiring diabetes in developing countries: case studies of Mozambique and Zambia. Diabetes Care. 2005;28(9):2136–40.CrossRefPubMedGoogle Scholar
  14. 14.
    McLarty DG, Kinabo L, Swai AB. Diabetes in tropical Africa: a prospective study, 1981–7. II. Course and prognosis. BMJ (Clinical research ed). 1990;300(6732):1107–10.CrossRefGoogle Scholar
  15. 15.
    Gill GV, Huddle KR, Rolfe M. Mortality and outcome of insulin-dependent diabetes in Soweto, South Africa. Diabetic Medicine. 1995;12(6):546–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Habtu E, Gill G, Tesfaye S. Characteristics of insulin requiring diabetes in rural northern Ethiopia—a possible link with malnutrition? Ethiop Med J. 1999;37(4):263–7.PubMedGoogle Scholar
  17. 17.
    Siraj ES, Reddy SSK, Scherbaum WA, Abdulkadir J, Hammel JP, Faiman C. Basal and postglucagon C-peptide levels in Ethiopians with diabetes. Diabetes Care. 2002;25(3):453–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Alemu S, Dessie A, Seid E, Bard E, Lee PT, Trimble ER, Phillips DIW, Parry EHO. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes? Diabetologia. 2009;52(9):1842–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Gill GV, Tekle A, Reja A, Wile D, English PJ, Diver M, Williams AJK, Tesfaye S. Immunological and C-peptide studies of patients with diabetes in northern Ethiopia: existence of an unusual subgroup possibly related to malnutrition. Diabetologia. 2011;54(1):51–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Mayer-Davis EJ, Beyer J, Bell RA, Dabelea D, D’Agostino R, Imperatore G, Lawrence JM, Liese AD, Liu L, Marcovina S, Rodriguez B. Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2009;32(Suppl 2):S112–22.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Marshall SL, Edidin DV, Arena VC, Becker DJ, Bunker CH, Gishoma C, Gishoma F, LaPorte RE, Kaberuka V, Sibomana L, Orchard TJ. Glucose control in Rwandan youth with type 1 diabetes following establishment of systematic, HbA1c based, care and education. Diabetes Res Clin Practice. 2015;107(1):113–22.CrossRefGoogle Scholar
  22. 22.
    Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes. 2012;61(11):2987–92.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2016

Authors and Affiliations

  • Sara L. Marshall
    • 1
  • Deborah V. Edidin
    • 2
  • Vincent C. Arena
    • 1
  • Dorothy J. Becker
    • 3
  • Clareann H. Bunker
    • 1
  • Crispin Gishoma
    • 4
  • Francois Gishoma
    • 4
  • Ronald E. LaPorte
    • 1
  • Vedaste Kaberuka
    • 4
  • Graham Ogle
    • 5
  • Wilson Rubanzana
    • 6
  • Laurien Sibomana
    • 1
  • Trevor J. Orchard
    • 1
  1. 1.University of Pittsburgh Graduate School of Public HealthPittsburghUSA
  2. 2.Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  3. 3.University of Pittsburgh School of MedicinePittsburghUSA
  4. 4.Association Rwandaise des DiabetiquesKigaliRwanda
  5. 5.International Diabetes Federation Life for a Child Program and Australian Diabetes CouncilSydneyAustralia
  6. 6.National University of RwandaKigaliRwanda

Personalised recommendations